Clinical-stage biotechnology company MetaVia Inc (Nasdaq:MTVA) said on Friday that it has built a strong global intellectual property portfolio supporting lead asset DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity and related metabolic disorders.

This includes 39 granted and pending patents in the United States and internationally, providing protection into 2041, unless extended further.

MetaVia's patent portfolio, exclusively licensed from Dong-A ST Co Ltd, provides broad protection covering the novel peptide structure of DA-1726 as well as its design as a long-acting dual-incretin therapy. Together, these protect both the core molecule and its therapeutic use in obesity, metabolic disease, and associated cardiometabolic conditions.

DA-1726 is intended to administered once weekly subcutaneously for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to MetaVia, in a Phase 1 multiple ascending dose trial in obesity the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction.